FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - FibroGen reported a quarterly loss of $0.16 per share, significantly worse than the Zacks Consensus Estimate of $0.03, representing an earnings surprise of -633.33% [1] - The company posted revenues of $2.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 71.19%, but down from $55.9 million in the same quarter last year [2] - Over the last four quarters, FibroGen has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - FibroGen shares have declined approximately 41.8% since the beginning of the year, compared to a -3.8% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.60 for the current fiscal year [4][7] - The current estimate revisions trend for FibroGen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which FibroGen belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact FibroGen's stock performance [5]